TruBridge, Inc.
HealthcareNASDAQ:TBRG · NASDAQ Global Select
+$0.05 today
Vol 0.23M · Avg 0.30M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.4%
avg -0.1%
ROIC
6.0%
avg 4.1%
ROA
1.1%
avg 0.5%
Analysis
ROIC is currently the strongest return metric at 6.0% versus its period average of 4.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher L. Fowler | Chief Executive Officer, President & Director | $1.20M | — | 50 | $136,772.00 | 0.91% |
Vinay Bassi | Chief Financial Officer & Treasurer | $828,750.00 | — | 55 | $50,499.00 | 0.34% |
Merideth Wilson | General Manager of Financial Health | $660,066.00 | — | 53 | $12,042.00 | 0.08% |
David Harse | General Manager of Patient Care | $601,892.00 | — | 49 | $21,091.00 | 0.14% |
Kevin Plessner | Secretary, Corporate Compliance Officer & General Counsel | $436,849.00 | — | 43 | $14,610.00 | 0.10% |
Amaris Angelica McComas | Chief People Officer | $372,859.00 | — | 43 | — | — |
Vita MacIntyre | Controller & Principal Accounting Officer | — | — | — | $2,687.00 | 0.02% |
Michael Daughton | Chief Business Officer | — | — | — | $68,064.00 | 0.45% |
Jamie Gier | Senior Vice President of Corporate Marketing & Head of Corporate Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
15
$5.70M
Sells
0
$0.00
Net Sentiment
+$5.70M
Net buying
Most Active
Pinetree Capital Ltd.
10 transactions
1–10 of 15
Analysis
Insiders reported 15 buys worth $5.70M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $5.70M. Pinetree Capital Ltd. was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +16.6% (8yr)1 analysts |
| Revenue | N/A | N/A | -1.5% | +5.5% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | +16.5% (8yr)1 analysts |
| EBIT | N/A | N/A | -3.2% | -10.3% (8yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at -1.5% over three years. Forward estimates point to EPS at +16.6% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cerus Corporation
NASDAQ:CERS
$512.94M
National Research Corporation
NASDAQ:NRC
$423.46M
SOPHiA GENETICS S.A.
NASDAQ:SOPH
$349.74M
Simulations Plus, Inc.
NASDAQ:SLP
$329.75M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Spok Holdings, Inc.
NASDAQ:SPOK
$227.67M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
OptimizeRx Corporation
NASDAQ:OPRX
$98.14M
Definitive Healthcare Corp.
NASDAQ:DH
$88.59M
Who manages TBRG?
TruBridge, Inc. (TBRG) lists 9 active executives. The top listed executive is David Harse, General Manager of Patient Care.
Are TBRG insiders buying or selling?
Recent insider activity shows net buying of $7.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.